Boltz launched as a public‑benefit corporation with $28 million in seed funding to democratize AI platforms for drug discovery and biomolecular design. Built by MIT CSAIL alumni and led by CEO Gabriele Corso, Boltz offers Boltz Lab and models touted to reach AlphaFold 3–level accuracy for complex prediction tasks, and aims to let scientists progress from hypothesis to human‑ready molecules in silico. In parallel, researchers unveiled FRAIL, a fragment‑based reinforcement learning framework for molecular optimization—another AI approach aimed at accelerating lead discovery. Together these moves highlight sustained investment in AI-native discovery tools that prioritize accessibility and reproducibility for academic and startup users. The Boltz launch and complementary computational innovations underscore continued convergence of open‑science models, venture capital support, and enterprise ambitions to reshape early‑stage drug R&D workflows.